Evolution of prospectively planned primary end points in completed CVOTs of antihyperglycemic treatments for type 2 diabetes, listed in order of year of.

Slides:

Advertisements

Similar presentations

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

Advertisements

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Clinical Outcomes with Newer Antihyperglycemic Agents

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

Study Design Scirica BM, Bhatt DL Braunwald et al, Sexagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

4S: Scandinavian Simvastatin Survival Study

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

Demystifying Cardiovascular Safety of Sulfonylurea.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

An initiative of South Asian Federation of Endocrine Societies (SAFES)

Prevalence (%) estimates of diabetes (20-79 years) 2010.

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes William B. White, M.D., Christopher P. Cannon, M.D., Simon R. Heller, M.D., Steven.

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.

Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents

The SPRINT Research Group

Cardiovascular Outcomes Trials with Antihyperglycemic Agents

LEADER trial: Primary Outcome

Disclosure Consultations and Honoraria Grant Support

Cardiovascular Outcomes Trials with Antihyperglycemic Agents

AIM HIGH Niacin plus Statin to prevent vascular events

SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.

Diabetes and Risk of CV Outcomes

Figure 6 Differences in glycaemic control with the study drug

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Antihyperglycemic Therapy

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials Sanjay Rajagopalan Journal of Indian College.

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Pharmacotherapy for Diabetic Coronary Disease:

Coronary artery bypass in patients with type 2 diabetes: Experience from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial Edward.

Potential mechanisms whereby statins may reduce the risk of stroke

(A) Meta-analysis of repeat revascularisation in randomised trials.

To bypass or stent? The changing rules of an advancing game

New frontiers in Diabetes management

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Delahoy PJ, et al. Clin Ther 2009;31:236-44

Characteristics of included studies

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Completed and ongoing CVOTs (6–14,39,44–58)

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

John J.V. McMurray et al. JCHF 2018;6:8-17

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Javier Escaned et al. JCIN 2018;11:

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Presentation transcript:

Evolution of prospectively planned primary end points in completed CVOTs of antihyperglycemic treatments for type 2 diabetes, listed in order of year of initiation (3,7,8,21,22,37–47). Evolution of prospectively planned primary end points in completed CVOTs of antihyperglycemic treatments for type 2 diabetes, listed in order of year of initiation (3,7,8,21,22,37–47). ACCORD, Action to Control Cardiovascular Risk in Diabetes; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation; BARI-2D, Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes; EXAMINE, Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care in Patients with Type 2 Diabetes and Acute Coronary Syndrome; FREEDOM-CVO, Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes; HEART-2D, Hyperglycemia and Its Effect after Acute Myocardial Infarction on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus; ORIGIN, Outcome Reduction with an Initial Glargine Intervention; SAVOR-TIMI 53, Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus—Thrombolysis in Myocardial Infarction 53; VADT, Veterans Affairs Diabetes Trial. *Includes events requiring hospitalization. †Includes fatal and nonfatal events. Nikolaus Marx et al. Dia Care 2017;40:1144-1151 ©2017 by American Diabetes Association